Nicholson Gregory S, Canty David, Southern Annemarie, Whelan Kevin, Brideau-Andersen Amy D, Broide Ron S
Allergan Aesthetics, an AbbVie Company, Irvine, CA 92612, USA.
Toxins (Basel). 2025 May 6;17(5):230. doi: 10.3390/toxins17050230.
TrenibotulinumtoxinE (trenibotE), a botulinum neurotoxin serotype E (BoNT/E), is being developed for clinical use, and can fill a unique treatment gap for patients who are seeking neurotoxin treatment with a rapid onset and short duration of effect. This preclinical study characterized the pharmacological activity of trenibotE using the mouse Digit Abduction Score (DAS) assay. A comparative analysis was also performed between trenibotE and an equi-efficacious dose of the botulinum neurotoxin serotype A (BoNT/A) onabotulinumtoxinA (onabotA). TrenibotE showed a dose-dependent increase in peak DAS and duration of effect. A comparison of onabotA and trenibotE in this assay at approximate equi-efficacious doses showed trenibotE to have a faster onset of effect (trenibotE yielded a significantly greater effect as early as 6 h post-injection), shorter time to peak effect (24-27 h vs. 2 days), and an overall shorter duration of response (3 days vs. 14 days). The unique temporal characteristics of trenibotE and pharmacological differentiation from onabotA observed in this preclinical assay support the clinical development of this molecule.
特瑞尼肉毒杆菌毒素E（trenibotE），一种E型肉毒杆菌神经毒素（BoNT/E），正在研发用于临床，可为寻求起效迅速且作用持续时间短的神经毒素治疗的患者填补独特的治疗空白。这项临床前研究使用小鼠数字外展评分（DAS）试验对特瑞尼肉毒杆菌毒素E的药理活性进行了表征。还对特瑞尼肉毒杆菌毒素E与等效剂量的A型肉毒杆菌神经毒素（BoNT/A）即保妥适（onabotA）进行了比较分析。特瑞尼肉毒杆菌毒素E的峰值DAS和作用持续时间呈剂量依赖性增加。在该试验中，对近似等效剂量的保妥适和特瑞尼肉毒杆菌毒素E进行比较，结果显示特瑞尼肉毒杆菌毒素E起效更快（特瑞尼肉毒杆菌毒素E在注射后6小时就产生了显著更大的效果），达到峰值效应的时间更短（24 - 27小时对2天），以及总体反应持续时间更短（3天对14天）。在这项临床前试验中观察到的特瑞尼肉毒杆菌毒素E独特的时间特征以及与保妥适的药理差异支持了该分子的临床开发。
